Literature DB >> 1317544

Antinociceptive and motor effects of delta/mu and kappa/mu combinations of intrathecal opioid agonists.

Christine Miaskowski1, Kimberly A Sutters, Yetunde O Taiwo, Jon D Levine.   

Abstract

Interactions between selective opioid agonists acting at spinal mu-, delta-, and kappa-opioid receptors were evaluated by co-administering a low-antinociceptive dose of the selective delta-agonist, DPDPE, or the selective kappa-agonist, U50,488H, with sequentially increasing doses of the selective mu-agonist, DAMGO, intrathecally. Antinociceptive synergy (i.e., a more than additive antinociceptive effect) was observed with both combinations of opioid agonists tested. The demonstration of antinociceptive synergy suggests that the subtypes of spinal opioid receptors can act, at least in part, through a common neural circuit. Since our measure of antinociception, the Randall-Selitto paw-withdrawal test, is dependent on a normally functioning motor system, we also evaluated the effects of these same combinations of opioid peptides on motor coordination using a rotarod treadmill. A low-antinociceptive dose of DPDPE or U50,488H co-administered intrathecally, with sequentially increasing doses of DAMGO, did not worsen the decrement in rotarod performance observed with the same doses of DAMGO administered as a single agent. In fact, the low-antinociceptive dose of DPDPE significantly attenuated the decrease in rotarod performance produced when the same dose of DAMGO was administered as a single agent. The results of this study suggest that intrathecal combinations of selective mu- with both delta- or kappa-selective opioid agonists can produce antinociceptive synergy without producing an increase in motor side effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317544     DOI: 10.1016/0304-3959(92)90200-U

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  11 in total

Review 1.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Pharmacotherapy of opioids: present and future developments.

Authors:  T F Meert
Journal:  Pharm World Sci       Date:  1996-01

3.  Role of µ, κ, and δ opioid receptors in tibial inhibition of bladder overactivity in cats.

Authors:  Zhaocun Zhang; Richard C Slater; Matthew C Ferroni; Brian T Kadow; Timothy D Lyon; Bing Shen; Zhiying Xiao; Jicheng Wang; Audry Kang; James R Roppolo; William C de Groat; Changfeng Tai
Journal:  J Pharmacol Exp Ther       Date:  2015-09-09       Impact factor: 4.030

4.  The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats.

Authors:  C Austin Zamarripa; Tanya Pareek; Hayley M Schrock; Thomas E Prisinzano; Bruce E Blough; Kenneth J Sufka; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2021-08-25       Impact factor: 4.530

5.  Evaluation of the interaction of mu and kappa opioid agonists on locomotor behavior in the horse.

Authors:  K R Mama; P J Pascoe; E P Steffey
Journal:  Can J Vet Res       Date:  1993-04       Impact factor: 1.310

6.  Clonidine and dexmedetomidine produce antinociceptive synergy in mouse spinal cord.

Authors:  Carolyn A Fairbanks; Kelley F Kitto; H Oanh Nguyen; Laura S Stone; George L Wilcox
Journal:  Anesthesiology       Date:  2009-03       Impact factor: 7.892

7.  The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies.

Authors:  Hong Xie; James H Woods; John R Traynor; Mei-Chuan Ko
Journal:  Anesth Analg       Date:  2008-06       Impact factor: 5.108

8.  Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8.

Authors:  Megan L Uhelski; Daniel Bruce; Rebecca Speltz; George L Wilcox; Donald A Simone
Journal:  Neuroscience       Date:  2020-08-25       Impact factor: 3.590

9.  Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; Kristen R Trexler; Kim Wix; Aubrie A Harland; Thomas E Prisinzano; Jeffrey Aubé; Steven G Kinsey; Terry Kenakin; David P Siderovski; Vincent Setola
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

10.  Ligand requirements for involvement of PKCε in synergistic analgesic interactions between spinal μ and δ opioid receptors.

Authors:  D J Schuster; M D Metcalf; K F Kitto; R O Messing; C A Fairbanks; G L Wilcox
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.